Figures & data
Table 1. Characteristics of the liposomes.
Figure 1. Optimization of ligand density of liposomes. HA-binding ratio of DOX-loaded liposomes with different densities of DSPE-PEG2000-Asp8 (A). Cellular uptake of DOX-loaded liposomes with different densities of DSPE-PEG2000-Folate (B) in MDA-MB-231 cells after incubation for 2 h at 37 °C (n = 3). *p < .05.
Figure 2. The cytotoxicity of free DOX and various liposomes containing DOX (n = 3). *p < .05.
Table 2. Pharmacokinetic parameters of DOX following intravenous administration of free DOX and various DOX-loaded liposomes (n = 6).
Figure 3. Biodistribution of Cy5.5 contained in various liposomes in mice bearing MDA-MB-231 tumors determined by an IVIS® Spectrum-CT.
Figure 4. In vivo therapeutic efficacy evaluation. Spontaneous time lifting of tumor-bearing right bind limb over a four-minute observation period (A). Number of flinches of tumor-bearing right hind limb over a four-minute observation period (B). Kaplan–Meier’s survival curves (C). Body weight changes in tumor-bearing mice after treatments with various samples (D) (n = 6). *p < .05.
Figure 5. In vivo safety evaluation. HE staining of major organ sections from mice receiving different formulations on the day 18 (A). Hematological indicators of RBC (B), WBC (C), and MCV (D) on day 18 after inoculation (n = 3). *p < .05.
